Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Latest News

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

News All Time

First Patient Dosed in Phase 2 Extension Study of Sabirnetug in Early Alzheimer Disease Louie Pasculli

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy Isabella Ciccone, MPH

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows Louie Pasculli

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

NeurologyLive® Brain Games: November 16, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

Elena Grebenciucova, MD, on Evolving Standards in NMOSD Diagnosis and Management Elena Grebenciucova, MD, Marco Meglio

The assistant professor of neurology at Northwestern University explained key diagnostic, therapeutic, and management considerations for clinicians caring for patients with NMOSD across diverse and evolving clinical scenarios.

This Week on NeurologyLive® — November 17, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Multidisciplinary Care Paths That Improve Neurosarcoidosis Management Spencer Hutto, MD, Marco Meglio

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

Recommended News For You

Even when they are not paying attention, children are still learning.

After two years, a significant left nasal obstruction was finally diagnosed.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

enhancing survivors of brain tumors' quality of life.

New policy review highlights the importance of health-related quality of life in advanced cancer

Study suggests radiation therapy benefits misjudged when clinical factors alone guide breast cancer treatment

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds

Recommended Articles For You

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies 

Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer 

An Overview Of Leukemia Cutis: What It Is And How To Treat It 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

2.

Dual-action mRNA vaccine takes aim at aggressive skin cancer

3.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

4.

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

5.

WHO launches plan for free child cancer medicines

1.

Immuno-Oncology in Daily Practice: Transforming Cancer Care One Patient at a Time

2.

The Importance of Iron Rich Foods in Preventing and Treating Anemia 

3.

Chondroma: What it is and How it Affects Your Health 

4.

Priming Agents: A Novel Approach to Enhancing Cell-Free DNA Detection in Liquid Biopsies

5.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

3.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot